Format

Send to

Choose Destination
Clin Transplant. 2015 Nov;29(11):1021-8. doi: 10.1111/ctr.12624. Epub 2015 Oct 5.

De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.

Author information

1
Department of Hepatobiliary Surgery and Transplantation, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.
2
Section Nephropathology, Institute of Pathology, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.
3
HLA Laboratory, Institute of Transfusion Medicine, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.
4
III. Medical Clinic/Nephrology, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.

Abstract

ABO-incompatible (ABOi) kidney transplantation (KTx) has become an accepted therapeutic option in renal replacement therapy for patients without a blood group-compatible living donor. Using different desensitization strategies, most centers apply B-cell depletion with rituximab and maintenance immunosuppression (IS) with tacrolimus and mycophenolic acid. This high load of total IS leads to an increased rate of surgical complications and virus infections in ABOi patients. Our aim was to establish ABOi KTx using an immunosuppressive regimen, which is effective in preventing acute rejection without increasing the risk for viral infections. Therefore, we selected a de novo immunosuppressive protocol with low-dose calcineurin inhibitor and the mTOR inhibitor everolimus for our ABOi program. Here, we report the first 25 patients with a complete three-yr follow-up treated with this regimen. Three-yr patient survival and graft survival were 96% and 83%. The rate of acute T-cell-mediated rejections was low (12%). Cytomegalovirus (CMV) infection was evident in one patient only (4%). Surgical complications were common (40%), but mild in 80% of cases. We demonstrate that ABOi KTx with a de novo mTOR inhibitor-based regimen is feasible without severe surgical or immunological complications and a low rate of viral infections.

KEYWORDS:

ABO-incompatible kidney transplantation; CMV; immunosuppression; mTOR inhibitor

PMID:
26333844
DOI:
10.1111/ctr.12624
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center